ClinicalTrials.gg
CompletedNCT00409682Updated Aug 4, 2011Results posted

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of Adalimumab and Adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 45 sites in 8 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-08-04.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
16th of 42
192 · median 143
Started
2007
with 3 others
Phase 3
22 of 42
none open now
Registered
8th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 16th largest by enrollment, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 8th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Read the detailed description

M06-806 (NCT # NCT00409682) was a Phase 3, multi-center, randomized, double-blind (DB), efficacy, safety, and pharmacokinetic (PK) study designed to evaluate the efficacy of 2 dose regimens for the induction and maintenance of clinical remission in pediatric subjects between the ages of 6 and 17 (inclusive) with moderate to severe Crohn's disease (CD) (defined by Pediatric Crohn's Disease Activity Index [PCDAI > 30]). Subjects must have either failed conventional therapy for CD or have previously received infliximab and lost response/had intolerance to infliximab.

Approximately 186 pediatric subjects between the ages of 6 and 17 were planned to be entered into the study at approximately 55 sites in the US, Canada, and Europe. At least 80 subjects were to be ≥ 13 years old at Baseline and one-third to one-half of the study population were to be subjects who had previously lost response or were intolerant to infliximab.

The duration of the study was to be up to 65 weeks, which included a 1- to 3-week Screening period, an Induction period, a Maintenance period, and a 70-day follow-up phone call for all subjects that either terminated early from the study or did not rollover into the extension study ([NCT # 00686374], to evaluate the long-term maintenance of clinical response, safety, and tolerability of repeated administration of adalimumab).

All subjects received an induction regimen administered at Baseline (Week 0) and Week 2. The open-label (OL) induction dose was based on the subject's Baseline body weight. Subjects weighing ≥ 40 kg were to receive 160 mg at Week 0 and 80 mg adalimumab at Week 2. Subjects weighing \< 40 kg were to receive 80 mg at Week 0 and 40 mg adalimumab at Week 2.

At Week 4, subjects were to be randomized 1:1 to 1 of 2 DB maintenance treatment groups (Low-Dose or High-Dose), stratified by Week 4 clinical responder status (clinical response was defined as decrease in PCDAI of ≥ 15 points from the Baseline score), body weight at Week 4 and prior exposure to infliximab. Subjects randomized to the High-Dose treatment group were to receive either 40 mg adalimumab subcutaneous (SC) every other week (eow) (if Week 4 body weight ≥ 40 kg) or 20 mg adalimumab SC eow (if Week 4 body weight \< 40 kg). Subjects randomized to the Low-Dose treatment group were to receive either 20 mg adalimumab SC eow (if Week 4 body weight ≥ 40 kg) or 10 mg adalimumab SC eow (if Week 4 body weight \< 40 kg).

Subject's body weight taken at Week 26 was to be used to readjust the maintenance dosing regimen for a subject whose body weight had increased from \< 40 kg to ≥ 40 kg during the study.

Subjects were expected to remain on blinded eow therapy throughout the 48-week study DB Maintenance period. However, starting at the Week 12 study visit, subjects who experienced a disease flare (increase in the PCDAI ≥ 15 points when compared to Week 4 and an absolute PCDAI above 30) or were non-responders (not achieving a decrease in the PCDAI score of at least 15 points when compared to the Baseline score for 2 consecutive visits at least 2 weeks apart) could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. During blinded ew treatment, if a subject continued to experience a flare or met the definition of non-response following an 8 week course of DB ew therapy, they were to be switched to OL ew therapy. The dosage of the OL ew therapy was 20 mg for subjects \< 40 kg and 40 mg for subjects ≥ 40 kg.

This study used the PCDAI to determine efficacy of the study drug. The primary efficacy endpoint is the proportion of subjects who are in clinical remission at Week 26, as measured by the PCDAI in the intent-to-treat population. Clinical remission is defined as a PCDAI score of ≤ 10.

The clinical response indicators include clinical remission as defined by PCDAI score at Week 52 and clinical response as defined by PCDAI score at Week 26 and at Week 52.

The patient reported outcome is the change from Baseline in total IMPACT III scores at Week 26 and Week 52.

The safety parameters (adverse events, laboratory data, and vital signs) were assessed at all visits throughout the study.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing.
  2. Subjects with a diagnosis of Crohn's disease for greater than 12 weeks prior to screening, confirmed by endoscopy or radiologic evaluation.
  3. PCDAI > 30 despite concurrent treatment with an oral , and/or azathioprine (AZA) or 6-mercaptopurine (6-MP) or methotrexate (MTX) as defined below:

    • Oral corticosteroid - Prednisone of ≥ 10 mg/day or equivalent, but not exceeding 40 mg, with a stable dose for at least two weeks prior to Baseline.
    • Azathioprine or 6-MP - AZA dose of ≥ 1.5 mg/kg/day or 6-MP dose of ≥ 1 mg/kg/day rounded to the nearest available tablet formulation, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
    • MTX dose of ≥ 5 mg once weekly, either subcutaneously (SC), intramuscularly (IM), or orally for subjects whose body weight is ≥ 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
    • MTX dose of 0.2 mg/kg, up to 5 mg, once weekly, either SC, IM, or orally for subjects whose body weight is \< 20 kg, or a dose that is the highest tolerated for the subject, in the opinion of the investigator (for example due to leukopenia, elevated liver enzymes, nausea, etc.) for at least 8 weeks prior to Baseline with a stable dose for at least 4 weeks prior to Baseline.
    • Concurrent therapy will not be required for subjects who within the past 2 years in the opinion of the Investigator have not responded to or could not tolerate systemic corticosteroids, AZA, 6-MP, or MTX as defined below:

      • Corticosteroids:

        • Failed to successfully respond to corticosteroids, or
        • Medical complications and/or adverse events (AEs) from corticosteroids that in the judgment of their physician, precludes their use (e.g. psychosis, uncontrolled diabetes, osteoporosis, or osteonecrosis).
      • Azathioprine, 6-MP or MTX: -

        • Failed to successfully respond to these drugs or
        • Medical complications and/or AEs that in the judgment of their physician, precludes their use (e.g. allergic reaction, pancreatitis, elevated liver enzymes, hepatitis or leukopenia).
  4. If female, subjects who were sexually active and were of practicing an approved method of throughout the study and for 150 days after study completion. Examples of approved methods of birth control included the following:

    • Condoms, sponge,foam,jellies,diaphragm, or intrauterine device (IUD)
    • Oral,parenteral, or intravaginal contraceptives for 12 weeks prior to adalimumab administration
    • A vasectomized partner.
  5. Parent or legal guardian,as required,had voluntarily signed and dated an form (IFC), approved by an Institutional Review Board (IRB)/ Independent Ethics Committee (IEC).
  6. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.
  7. Parent or legal guardian was willing to actively supervise storage and administration of study drug and to ensure that the time of each dose was accurately recorded in the subject's diary.
  8. Subjects who had previously received infliximab, providing the subject had an initial response and then discontinued use due to a loss of response, or discontinued use due to intolerance.

Exclusion criteria

Exclusion Criteria:

  1. History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma-in-situ of the cervix.
  2. History of listeria, histoplasmosis, chronic or active infection, (HIV), an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease, or active tuberculosis (TB) (receiving treatment or not receiving treatment), severe infections such as sepsis and opportunistic infections.
  3. Subject with infectious colitis, ulcerative colitis or indeterminate colitis as determined by the investigator and Abbott Medical Monitor.
  4. Subject with symptomatic known obstructive strictures.
  5. Subject who had surgical bowel resections within the past 24 weeks of the Baseline visit or planned any resection at any time point while enrolled in the study.
  6. Subject with an ostomy or ileo-anal pouch. (Subjects with a previous ileo-rectal anastomosis were not excluded).
  7. Subject who had short bowel syndrome as determined by the investigator.
  8. Subject who was currently receiving total parenteral nutrition (TPN).
  9. Females who were pregnant or were currently breast-feeding.
  10. Subject who had received any chemical agent in the past 30 days or 5 half-lives prior to Baseline (whichever was longer).
  11. Subject who had received any investigational biological agent in the past 16 weeks or 5 half-lives prior to Baseline (whichever was longer).
  12. Subject who has had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to Baseline for any non-Crohn's related infections.
  13. Subject with a history of drug or alcohol abuse in the last year.
  14. Subjects with a poorly controlled medical condition such as: uncontrolled diabetes, recurrent infections, unstable ischemic heart disease, moderate to severe heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the investigator or the Sponsor, would put the subject at risk by participation in the protocol.
  15. Subjects with positive C. difficile stool assay.
  16. Subject who previously used infliximab within eight weeks of Baseline.
  17. Subject who previously used infliximab and had not clinically responded at any time ("primary non-responder") unless subject experienced a treatment limiting reaction to infliximab.
  18. Previous treatment with any other anti-TNF agent except infliximab.
  19. Received previous treatment with adalimumab or previous participation in an adalimumab clinical study.
  20. Screening laboratory and other analyses showing any of the following abnormal results:

    • (ECG) - with clinically significant abnormalities;
    • (AST) or alanine transaminase (ALT) >1.75 x the upper limit of the reference range;
    • Total ≥ 3 mg/dL;
    • Serum creatinine > 1.6 mg/dL;
  21. Subjects on AZA, 6-MP, or MTX who had not been on these medications for at least 8 weeks prior to Baseline and on stable doses of these medications for at least 4 weeks prior to Baseline. Subjects who had been on AZA, 6-MP, or MTX who had discontinued these medications within 8 weeks of Baseline.
  22. Subjects on aminosalicylates, or Crohn's-related antibiotics (fluoroquinolones such as ciprofloxacin or nitroimidazole derivatives such as metronidazole) that had not been on stable doses of these medications for at least 4 weeks prior to Baseline. In addition, subjects on aminosalicylates or Crohn's-related antibiotic treatments who had discontinued these medications within four weeks of Baseline.
  23. Subjects on prednisone > 40 mg/day (or equivalent) or subjects on \< 10 mg/day prednisone and subjects who were not on a stable dose for at least 2 weeks prior to Baseline. In addition, subjects who discontinued prednisone (or equivalent) within 2 weeks of Baseline.
  24. Subjects on growth hormone that had not been on a stable dose for at least 12 weeks prior to Baseline. Subjects had to consent to remain on a stable dose through the duration of the study.
  25. Subjects on budesonide > 9 mg/day and subjects who were not on stable doses for at least 2 weeks prior to Baseline. In addition, subjects who discontinued budesonide within 2 weeks of Baseline.
  26. Subjects who were currently taking both budesonide and prednisone (or equivalent).
  27. Subjects who had undergone therapeutic enemas within two weeks prior to Baseline.
  28. Subjects who had been on cyclosporine (intravenous [IV], oral), tacrolimus (any form), or mycophenolate mofetil within 28 days of Baseline.
  29. Subjects who had been on Kineret® (anakinra) must discontinue use 2 days prior to Baseline.
  30. Subjects with any prior exposure to Tysabri (natalizumab).
  31. Subjects with known to the of adalimumab as stated in the label.
  32. Subjects with a previous history of dysplasia of the gastrointestinal tract.
  33. Subjects who weighed \< 17 kg at Screening.
  34. Subject not in compliance with prior and concomitant medications.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Active comparator
    Open-label adalimumab (Week 0 to Week 4)

    All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.

    Biological: Adalimumab

  • Active comparator
    Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)

    Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.

    Biological: Adalimumab

  • Active comparator
    High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)

    Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.

    Also known as: ABT-D2E7, adalimumab, Humira

  • BiologicalAdalimumab

    Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.

    Also known as: ABT-D2E7, adalimumab, Humira

  • BiologicalAdalimumab

    Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.

    Also known as: ABT-D2E7, adalimumab, Humira

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The primary endpoint was clinical remission as defined by PCDAI score ≤ 10. The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to-treat population.

    Time frame: Week 26

Secondary outcomes

  1. Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 52

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100 with higher scores indicating more active disease. Clinical remission was defined as PCDAI score of ≤ 10. The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to treat population.

    Time frame: Week 52

  2. Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 26

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.

    Time frame: Week 26

  3. Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 52

    Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.

    Time frame: Week 52

  4. Change From Baseline IMPACT III Scores at Week 26 (Observed Case)

    The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn's disease \[CD\] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good 'quality of life' condition) through 1 (bad 'quality of life' condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.

    Time frame: Baseline and Week 26

  5. Change From Baseline IMPACT III Scores at Week 52 (Observed Case)

    The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn's disease \[CD\] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good 'quality of life' condition) through 1 (bad 'quality of life' condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.

    Time frame: Baseline and Week 52

07

Results

Posted Aug 4, 2011
Limitations and caveats
Absence of placebo group comparative data.

Participant flow

Subjects were enrolled at 45 investigative sites in the US, Canada, and Europe. A total of 192 subjects received at least one dose of adalimumab and participated in the 4-week Open-label induction period of the study. Of these, 4 discontinued and 188 subjects participated in the DB Maintenance period.

Open-label Induction Period
Participant flow — Open-label Induction Period
MilestoneOpen-label Adalimumab (Week 0 to Week 4)Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Started19200
Completed18800
Not completed400
Withdrew: Adverse event100
Withdrew: Lack of efficacy100
Withdrew: Protocol violation100
Withdrew: Subject did not satisfy entry criteria100
EOW Double-blind Maintenance Period
Participant flow — EOW Double-blind Maintenance Period
MilestoneOpen-label Adalimumab (Week 0 to Week 4)Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Started09593
Completed05866
Not completed03727
Withdrew: Adverse event01012
Withdrew: Lack of efficacy01811
Withdrew: Lost to follow-up010
Withdrew: Withdrawal by subject042
Withdrew: Protocol violation041
Withdrew: Non-compliance001

Outcome measures

PrimaryPercent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The primary endpoint was clinical remission as defined by PCDAI score ≤ 10. The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to-treat population.

Time frame:
Week 26
Reported as:
Number · percent of participants
Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26
percent of participantsLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 2628.438.7
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · Cochran-Mantel-Haenszel · p = 0.075 (There is no adjustment for multiple comparison on the primary outcome measure.) · Mean difference (net): 10.29 · 95% CI -3.14 to 23.71Difference is between adalimumab High-dose and adalimumab Low-dose group.
SecondaryPercent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 52

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100 with higher scores indicating more active disease. Clinical remission was defined as PCDAI score of ≤ 10. The comparison was between High-Dose adalimumab versus Low-Dose adalimumab in the intent-to treat population.

Time frame:
Week 52
Reported as:
Number · percent of participants
Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 52
percent of participantsLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Percent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 5223.233.3
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · Cochran-Mantel-Haenszel · p = 0.100 (The hierarchical stepwise closed testing procedure was implemented to control the overall significance level at 0.05 in the ITT population.) · Mean difference (net): 10.18 · 95% CI -2.62 to 22.97A significance test for any individual major secondary efficacy endpoint in the hierarchy was to be inferential only if the hypothesis tests of all preceding major secondary efficacy endpoints were statistically significant at 0.050.
SecondaryPercent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 26

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.

Time frame:
Week 26
Reported as:
Number · percent of participants
Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 26
percent of participantsLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 2648.459.1
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · Cochran-Mantel-Haenszel · p = 0.073 (The hierarchical stepwise closed testing procedure was implemented to control the overall significance level at 0.05 in the ITT population) · Mean difference (net): 10.72 · 95% CI -3.45 to 24.89A significance test for any individual major secondary efficacy endpoint in the hierarchy was to be inferential only if the hypothesis tests of all preceding major secondary efficacy endpoints were statistically significant at 0.050.
SecondaryPercent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 52

Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's Disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, examination of abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical response was defined as a decrease from Baseline in the PCDAI score of at least 15 points. The comparison was High-Dose adalimumab versus Low-Dose in the ITT population.

Time frame:
Week 52
Reported as:
Number · percent of participants
Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 52
percent of participantsLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Percent of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score at Week 5228.441.9
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · Cochran-Mantel-Haenszel · p = 0.038 (The hierarchical stepwise closed testing procedure was implemented to control the overall significance level at 0.05 in the ITT population) · Mean difference (net): 13.51 · 95% CI -0.01 to 27.04A significance test for any individual major secondary efficacy endpoint in the hierarchy was to be inferential only if the hypothesis tests of all preceding major secondary efficacy endpoints were statistically significant at 0.050.
SecondaryChange From Baseline IMPACT III Scores at Week 26 (Observed Case)

The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn's disease \[CD\] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good 'quality of life' condition) through 1 (bad 'quality of life' condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.

Time frame:
Baseline and Week 26
Reported as:
Mean · Scores on a scale
Change From Baseline IMPACT III Scores at Week 26 (Observed Case)
Scores on a scaleLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Change From Baseline IMPACT III Scores at Week 26 (Observed Case)26.40 ± 15.58923.70 ± 18.990
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · ANCOVA · p = 0.161 (The hierarchical stepwise closed testing procedure was implemented to control the overall significance level at 0.05 in the ITT population.) · Mean difference (net): -4.10 · 95% CI -9.86 to 1.66Difference is between adalimumab High-dose and adalimumab Low-dose groups. Baseline means include subjects who had both Baseline and post-Baseline measurements.
SecondaryChange From Baseline IMPACT III Scores at Week 52 (Observed Case)

The IMPACT III questionnaire is a 35-item assessment of health-related quality of life in patients with inflammatory bowel disease (Crohn's disease \[CD\] or ulcerative colitis). In this study, subjects greater than or equal 10 years old who had CD at baseline completed an IMPACT III questionnaire at Baseline, Week 26, and Week 52. Subjects marked an option from 1 to 5 for each item left to right with numbers 5 (good 'quality of life' condition) through 1 (bad 'quality of life' condition). The total scores, range from 35 to 175 with higher scores representing a better quality of life.

Time frame:
Baseline and Week 52
Reported as:
Mean · Scores on a scale
Change From Baseline IMPACT III Scores at Week 52 (Observed Case)
Scores on a scaleLow-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
Change From Baseline IMPACT III Scores at Week 52 (Observed Case)26.49 ± 16.18224.25 ± 14.678
Statistical analysis
  • Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52) vs High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52) · ANCOVA · p = 0.735 · Mean difference (net): -1.00 · 95% CI -6.88 to 4.88Difference is between adalimumab High-dose and adalimumab Low-dose groups. Baseline means include subjects who had both Baseline and post-Baseline measurements.

Adverse events

Collected over All adverse events (AEs) reported from the time of study drug administration until 70 days after discontinuation of study drug were collected. Serious AEs were collected from the time the subject or parent/legal guardian signed the informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Adalimumab (Week 0 to Week 4)—6/192 (3.1%)64/192 (33.3%)
Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)—19/95 (20%)62/95 (65.3%)
High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)—22/93 (23.7%)69/93 (74.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventOpen-label Adalimumab (Week 0 to Week 4)Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
CROHN'S DISEASEGastrointestinal disorders2/19215/9512/93
ANAEMIABlood and lymphatic system disorders0/1920/954/93
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders0/1920/951/93
ABDOMINAL ABSCESSInfections and infestations0/1920/951/93
ANAL ABSCESSInfections and infestations0/1920/951/93
GASTROENTERITISInfections and infestations0/1920/951/93
H1N1 INFLUENZAInfections and infestations0/1920/951/93
HISTOPLASMOSIS DISSEMINATEDInfections and infestations0/1920/951/93
PSYCHOSOMATIC DISEASEPsychiatric disorders0/1920/951/93
PANCREATITIS ACUTEGastrointestinal disorders0/1921/950/93
Most frequent other events
Showing 10 of 27
Most frequent other events
EventOpen-label Adalimumab (Week 0 to Week 4)Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)
HEADACHENervous system disorders9/19220/9516/93
CROHN'S DISEASEGastrointestinal disorders5/19215/9511/93
NASOPHARYNGITISInfections and infestations3/19211/959/93
NAUSEAGastrointestinal disorders9/1926/9510/93
PYREXIAGeneral disorders1/1928/9510/93
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/19210/9510/93
VOMITINGGastrointestinal disorders3/19210/956/93
ABDOMINAL PAINGastrointestinal disorders5/1926/959/93
COUGHRespiratory, thoracic and mediastinal disorders0/1927/959/93
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders3/1928/959/93

Baseline characteristics

Age Continuous
Age Continuous(years)Open-label Adalimumab (Week 0 to Week 4)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)Low-Dose Adalimumab: 20 mg or 10 mg (Week 4 to Week 52)Total
Mean0 ± 013.7 ± 2.5213.5 ± 2.4713.6 ± 2.49
Age, Customized
Age, Customized(years)Open-label Adalimumab (Week 0 to Week 4)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)Low-Dose Adalimumab: 20 mg or 10 mg (Week 4 to Week 52)Total
< 130313566
>= 1306260122
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Adalimumab (Week 0 to Week 4)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)Low-Dose Adalimumab: 20 mg or 10 mg (Week 4 to Week 52)Total
Female0424183
Male05154105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Open-label Adalimumab (Week 0 to Week 4)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)Low-Dose Adalimumab: 20 mg or 10 mg (Week 4 to Week 52)Total
White08185166
Black05611
Asian0303
American Indian/Alaska Native0000
Native Hawaiian or other Pacific Islander0000
Mult-race0123
Other0325
Weight
Weight(kg)Open-label Adalimumab (Week 0 to Week 4)High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)Low-Dose Adalimumab: 20 mg or 10 mg (Week 4 to Week 52)Total
< 400323567
>= 4006160121
08

Study locations

45 sites
  • Site Reference ID/Investigator# 10287
    Los Angeles, California 90095-1752, United States
  • Site Reference ID/Investigator# 5223
    Orange, California 92868, United States
  • Site Reference ID/Investigator# 4984
    San Francisco, California 94143, United States
  • Site Reference ID/Investigator# 5222
    Aurora, Colorado 80045, United States
  • Site Reference ID/Investigator# 5676
    Hartford, Connecticut 06106, United States
  • Site Reference ID/Investigator# 4911
    Orlando, Florida 32801, United States
  • Site Reference ID/Investigator# 7640
    Orlando, Florida 32806, United States
  • Site Reference ID/Investigator# 5904
    Atlanta, Georgia 30342, United States
  • Site Reference ID/Investigator# 4316
    Chicago, Illinois 60637, United States
  • Site Reference ID/Investigator# 5901
    Maywood, Illinois 60153, United States
  • Site Reference ID/Investigator# 4912
    Indianapolis, Indiana 46202, United States
  • Site Reference ID/Investigator# 4317
    Baltimore, Maryland 21287, United States
  • Site Reference ID/Investigator# 5102
    Rochester, Minnesota 55905, United States
  • Site Reference ID/Investigator# 4285
    St. Paul, Minnesota 55114, United States
  • Site Reference ID/Investigator# 3826
    Las Vegas, Nevada 89109, United States
  • Site Reference ID/Investigator# 6182
    Morristown, New Jersey 07962, United States
  • Site Reference ID/Investigator# 8801
    Buffalo, New York 14222, United States
  • Site Reference ID/Investigator# 3734
    Mineola, New York 11501, United States
  • Site Reference ID/Investigator# 4913
    New Hyde Park, New York 11040, United States
  • Site Reference ID/Investigator# 6257
    Chapel Hill, North Carolina 27599, United States
  • Site Reference ID/Investigator# 4909
    Cincinnati, Ohio 45229, United States
  • Site Reference ID/Investigator# 4914
    Columbus, Ohio 43205, United States
  • Site Reference ID/Investigator# 5892
    Philadelphia, Pennsylvania 19104, United States
  • Site Reference ID/Investigator# 6354
    Nashville, Tennessee 37232, United States
  • Site Reference ID/Investigator# 4983
    Seattle, Washington 98105, United States
  • Site Reference ID/Investigator# 4950
    Milwaukee, Wisconsin 53226, United States
  • Site Reference ID/Investigator# 6700
    Antwerp, 2020, Belgium
  • Site Reference ID/Investigator# 7744
    Brussels, 1020, Belgium
  • Site Reference ID/Investigator# 6073
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 5109
    Calgary, T3B 6A8, Canada
  • Site Reference ID/Investigator# 4916
    Halifax, 83K 6R8, Canada
  • Site Reference ID/Investigator# 10284
    Hamilton, L8N 3Z5, Canada
  • Site Reference ID/Investigator# 8391
    London, N6A 5W9, Canada
  • Site Reference ID/Investigator# 5169
    Ottawa, K1H 8L1, Canada
  • Site Reference ID/Investigator# 6798
    Toronto, M5G 1X8, Canada
  • Site Reference ID/Investigator# 5570
    Vancouver, V6H 3V4, Canada
  • Site Reference ID/Investigator# 6071
    Prague 5, 15006, Czech Republic
  • Site Reference ID/Investigator# 6065
    Paris, 75015, France
  • Site Reference ID/Investigator# 6072
    Paris, 75019, France
  • Site Reference ID/Investigator# 16501
    Amsterdam, 1100 DD, Netherlands
  • Site Reference ID/Investigator# 14750
    Nijmegen, 6500HB, Netherlands
  • Site Reference ID/Investigator# 13622
    Rotterdam, 3015 GJ, Netherlands
  • Site Reference ID/Investigator# 6428
    Warsaw, 04-730, Poland
  • Site Reference ID/Investigator# 6430
    Wroclaw, 50-369, Poland
  • Site Reference ID/Investigator# 7742
    London, E1 1BB, United Kingdom
09

References and documents

Publications

  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗
  • Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018 Nov 9;12(10):1249-1254. doi: 10.1093/ecco-jcc/jjy087. PubMed 29939254 ↗
  • Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012 Aug;143(2):365-74.e2. doi: 10.1053/j.gastro.2012.04.046. Epub 2012 May 2. PubMed 22562021 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2006
First posted
Dec 11, 2006
Start
Apr 2007
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
Aug 4, 2011
Last update
Aug 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00409682
Lead sponsor
Abbott
First posted
Dec 11, 2006
Start date
Apr 2007
Primary completion
May 2010
Completion
May 2010
Results posted
Aug 4, 2011
Last update
Aug 4, 2011

Study contacts

Roopal Thakkar
study director · Abbott

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion